



Wisconsin Department of Health Services
State Disaster Medical Advisory Committee (SDMAC)
Therapeutics Subcommittee
DRAFT Discussion and Action Items

Date: Friday, November 6, 2020
Time: 12:00 to 1:00 PM
Remote Link:
<https://dhs.wi.zoom.us/j/94669991278> Call In: 1
646 558 8656; 980 2058 6371

Therapeutics Subcommittee Nov 6 Meeting Recording must use Edge or Chrome

Meeting Invitees:

X	Alyson Capp, PhD (co-chair) Director of Ethics Advocate Aurora Health	X	Helen Marks Dicks, JD State Issues Advocacy Director AARP Wisconsin	X	Steven R Leuthner, MD, MA Neonatal-Perinatal Medicine and Center for Bioethics MCW & Children's Wisconsin	X	J. Njeri Wainaina, MD Associate Professor Medical College of Wisconsin
X	Sarah Sorum, PharmD (co-chair) Executive Vice President & CEO Pharmacy Society of Wisconsin	X	J. Paul Kelleher, PhD Associate Professor UW-Madison	X	Eric Marty, MD Director of Palliative Care Agrace	X	Margret Nolan, MD, MS Physician Scientist UW Madison
X	Dennis Brierton, Pharm D, BCPS, FASHP System Director, Clinical Pharmacy Advocate Aurora Health	X	Mohammad (Mo) Kharbat - MBA, BPharm, R.Ph., BCPS Regional VP of Pharmacy Services SSM Health	X	Sridevi Mohan, MPH, MA Epidemiologist Public Health Madison & Dane County	X	M. Preston Leavitt SDMAC Therapeutics Subcommittee PM Support American Family Insurance
X	Gina Dennik-Champion, MSN, RN, MSHA Executive Director Wisconsin Nursing Association	X	Elizabeth (Liz) Laubach, PharmD, BCPS Regional Director of Pharmacy Ascension Wisconsin	X	Carlo Nevicosi, APSW deputy director Walworth County Health & Human Services		Kathleen Caron SDMAC PM Support Lead WI Department of Health Services Division of Public Health

Agenda:

Time:	Topic:	Lead:	Follow-up Items:
12:01 to 12:06 PM	Opening, introduction of new members, and roll call	Preston Leavitt	<ul style="list-style-type: none"> 13 of 13 committee members were present and a quorum was attained for the meeting to proceed
12:06 to 12:09 PM	Review and approval of minutes from October 23rd and 30th, 2020 meeting	Preston Leavitt	<ul style="list-style-type: none"> Helen Marks Dicks moved to approve the Minutes, Steven R Leuthner second.
12:09 to 12:13 PM	Announce Tuesday's at noon as new meeting time	Alyson Capp	<ul style="list-style-type: none"> Announced that the Therapeutics subcommittee will be meeting 2x per week beginning the week of November 8. The two meeting times will be Tuesdays at 12:00 – 1:00 PM and Fridays at 12:00 – 1:00 PM
12:13 to 12: PM	Review of Ely Lilly EUA Request Document	Alyson Capp	<ul style="list-style-type: none"> General discussion on the merits, potentials, and risks for the new EUA Request by Ely Lilly, which at this point, shows to have limited doses available for allocation per state (around 6000-10000 as a current estimate) Key benefit of this drug is to prevent the progression of the disease and not prevent the transmission of the virus. Discussion around the validity of different potential allocation methods.



Wisconsin Department of Health Services
State Disaster Medical Advisory Committee (SDMAC)
Therapeutics Subcommittee
DRAFT Discussion and Action Items

Date: Friday, November 6, 2020
Time: 12:00 to 1:00 PM
Remote Link:
<https://dhs.wi.zoom.us/j/94669991278> Call In: 1
646 558 8656; 980 2058 6371

Time:	Topic:	Lead:	Follow-up Items:
			<ul style="list-style-type: none">○ Randomization may not work due to the timing needed in administering this drug early and not necessarily having a constant pool of individuals that meet the criteria.○ First come-first serve was discussed, again due to the timing need○ Discussion around the distribution to specific facilities that have potential for higher-impacted individuals, (such as skilled nursing facilities)○ Discussion was held around the risk of distributing through healthcare systems and the potential harm that could be done to those who do not have access to healthcare systems.● The issue of informed consent was brought forward, and the additional consent needed due to the lack of historical data on an EUA type drug. This would most likely be done through a FAQ sheet and a “disclosure discussion” (as recommended by the FDA).● Tactical discussion was held to better understand the process steps within a healthcare system of billing, screening, administration, etc. for a limited allocation drug.
12: to 1: PM	Discussion on charge questions 1 & 2 <ul style="list-style-type: none">● Begin documenting a decision tree for Charge Question 1● Discussion of decision processes in the event that a drug is made available to the state.	Alyson Capp	<ul style="list-style-type: none">● Safety considerations would create some impetus for sending through health systems● However, this does create potential for harm for those who do not have ready access or general connection to those who are not connected to a health system.● Alyson has volunteered to put together an initial draft of a decision tree.● Planning for next Tuesday, the conversations will focus on<ul style="list-style-type: none">○ a discussion regarding potential scenarios that may come up in the distribution of a drug○ a discussion on the Allocation Playbook distributed by the CDC
1:00 PM	Adjourn	Alyson Capp	<ul style="list-style-type: none">● Meeting was adjourned at 1:00 PM